Population Pharmacokinetics of Propofol: A Multicenter Study

Background: Target-controlled infusion is an increasingly common type of administration for propofol. This method requires accurate knowledge of pharmacokinetics, including the effects of age and weight. The authors performed a multicenter population analysis to quantitate the effects of covariates. Methods: The authors analyzed 4,112 samples of 270 individuals (150 men, 120 women, aged 2–88 yr, weighing 12–100 kg). Population pharmacokinetic modeling was performed using NONMEM (NONMEM Project Group, University of California, San Francisco, CA). Inter- and intraindividual variability was estimated for clearances and volumes. The effects of age, weight, type of administration and sampling site were investigated. Results: The pharmacokinetics of propofol were best described by a three-compartment model. Weight was found to be a significant covariate for elimination clearance, the two intercompartmental clearances, and the volumes of the central compartment, the shallow peripheral compartment, and the deep peripheral compartment; power functions with exponents smaller than 1 yielded the best results. The estimates of these parameters for a 70-kg adult were 1.44 l/min, 2.25 l/min, 0.92 l/min, 9.3 l, 44.2 l, and 266 l, respectively. For patients older than 60 yr the elimination clearance decreased linearly. The volume of the central compartment decreased with age. For children, all parameters were increased when normalized to body weight. Venous data showed a decreased elimination clearance; bolus data were characterized by increases in the volumes of the central and shallow peripheral compartments and in the rapid distribution clearance (Cl2) and a decrease in the slow distribution clearance (Cl3). Conclusions: Pharmacokinetics of propofol can be well described by a three-compartment model. Inclusion of age and weight as covariates significantly improved the model. Adjusting pharmacokinetics to the individual patient should improve the precision of target-controlled infusion and may help to broaden the field of application for target-controlled infusion systems.

[1]  H F Nicodemus,et al.  The Pharmacokinetics of Propofol in Children Using Three Different Data Analysis Approaches , 1994, Anesthesiology.

[2]  T. Buckley,et al.  PHARMACOKINETICS OF PROPOFOL IN WOMEN UNDERGOING ELECTIVE CAESAREAN SECTION , 1990 .

[3]  A. Burm,et al.  Performance of Computer-Controlled Infusion of Propofol: An Evaluation of Five Pharmacokinetic Parameter Sets , 1995, Anesthesia and analgesia.

[4]  R. Jones,et al.  Pharmacokinetics of propofol in children. , 1990, British journal of anaesthesia.

[5]  H. Schwilden,et al.  Prädiktivität und Präzision einer „target-controlled infusion” (TCI) von Propofol mit dem System „Disoprifusor TCI®” , 1998, Der Anaesthesist.

[6]  D. Morgan,et al.  Pharmacokinetics of propofol when given by intravenous infusion. , 1990, British journal of clinical pharmacology.

[7]  A. Yli-Hankala,et al.  Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. , 1992, British journal of anaesthesia.

[8]  M. White,et al.  Intravenous propofol anaesthesia using a computerised infusion system , 1990, Anaesthesia.

[9]  M. White,et al.  Induction of anaesthesia with propofol using a target‐controlled infusion system , 1992, Anaesthesia.

[10]  C. Reilly,et al.  Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. , 1990, British journal of anaesthesia.

[11]  S L Shafer,et al.  Pharmacokinetics and Pharmacodynamics of Propofol Infusions during General Anesthesia , 1988, Anesthesiology.

[12]  R. Farinotti,et al.  Pharmacokinetics and Protein Binding of Propofol in Patients with Cirrhosis , 1988, Anesthesiology.

[13]  E. Gepts,et al.  Disposition of Propofol Administered as Constant Rate Intravenous Infusions in Humans , 1987, Anesthesia and analgesia.

[14]  C. Saint-Maurice,et al.  Pharmacokinetics of propofol in young children after a single dose. , 1989, British journal of anaesthesia.

[15]  Thomas W. Schnider,et al.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development , 1997 .

[16]  M. A. Hughes,et al.  Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. , 1992, Anesthesiology.

[17]  A. McEwan,et al.  The Interaction of Fentanyl on the Cp50 of Propofol for Loss of Consciousness and Skin Incision , 1994, Anesthesiology.

[18]  H. Schwilden,et al.  Pharmacokinetic and pharmacodynamic modelling of propofol ('Diprivan') in volunteers and surgical patients. , 1985, Postgraduate medical journal.

[19]  H Schwilden,et al.  Total intravenous anaesthesia with propofol and alfentanil by computer‐assisted infusion , 1988, Anaesthesia.

[20]  H. Sonntag,et al.  Hepatic and extrahepatic disposition of propofol in patients undergoing coronary bypass surgery. , 1990, British journal of anaesthesia.

[21]  I. Cockshott.  Propofol ('Diprivan') pharmacokinetics and metabolism--an overview. , 1985, Postgraduate medical journal.

[22]  J. Glen,et al.  Pharmacokinetic Model Selection for Target Controlled Infusions of Propofol: Assessment of Three Parameter Sets , 1994, Anesthesiology.

[23]  E. Vandermeersch,et al.  Pharmacokinetics of propofol during continuous infusion for pediatric anesthesia. , 1989, Acta anaesthesiologica Belgica.

[24]  S. Shafer,et al.  The Influence of Method of Administration and Covariates on the Pharmacokinetics of Propofol in Adult Volunteers , 1998, Anesthesiology.

[25]  S L Shafer,et al.  Pharmacokinetics of Propofol in Adult Patients Undergoing Coronary Revascularization , 1996, Anesthesiology.

[26]  M. White,et al.  Pharmacokinetics of propofol in female patients. Studies using single bolus injections. , 1987, British journal of anaesthesia.

[27]  E. J. Douglas,et al.  Pharmacokinetics of propofol (diprivan) in elderly patients. , 1988, British journal of anaesthesia.

[28]  P. Parkin,et al.  Severe hypertension and raised haematocrit: unusual presentation of Guillain-Barré syndrome. , 1985, Postgraduate medical journal.

[29]  V Maes,et al.  Disposition kinetics of propofol during alfentanil anaesthesia , 1988, Anaesthesia.

[30]  J T Harvey,et al.  Computer controlled infusion of propofol. , 1989, British journal of anaesthesia.

[31]  G. Plummer.  Improved method for the determination of propofol in blood by high-performance liquid chromatography with fluorescence detection. , 1987, Journal of chromatography.

[32]  B. Lacarelle,et al.  Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients. , 1990, Anesthesiology.

[33]  J. Sear,et al.  Disposition of propofol in patients undergoing surgery. A comparison in men and women. , 1986, British journal of anaesthesia.

[34]  G. Bailie,et al.  Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. , 1992, British journal of anaesthesia.

[35]  N. Morton,et al.  Pharmacokinetic model driven infusion of propofol in children. , 1991, British journal of anaesthesia.

[36]  T. M. Savege,et al.  Influence of sample site on blood concentrations of ICI 35868. , 1983, British journal of anaesthesia.

[37]  S. Fan,et al.  Propofol Concentration Monitoring in Plasma or Whole Blood by Gas Chromatography and High-Performance Liquid Chromatography , 1995, Anesthesia and analgesia.